These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31985460)

  • 21. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.
    Jones RW; Lebrec J; Kahle-Wrobleski K; Dell'Agnello G; Bruno G; Vellas B; Argimon JM; Dodel R; Haro JM; Wimo A; Reed C
    Dement Geriatr Cogn Dis Extra; 2017; 7(1):87-100. PubMed ID: 28611822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.
    Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A;
    J Nutr Health Aging; 2010 Oct; 14(8):648-54. PubMed ID: 20922341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consequences of Anosognosia on the Cost of Caregivers' Care in Alzheimer's Disease.
    Turró-Garriga O; Garre-Olmo J; Reñé-Ramírez R; Calvó-Perxas L; Gascón-Bayarri J; Conde-Sala JL
    J Alzheimers Dis; 2016 Oct; 54(4):1551-1560. PubMed ID: 27636844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.
    Kosaner Kließ M; Martins R; Connolly MP
    J Prev Alzheimers Dis; 2021; 8(3):362-370. PubMed ID: 34101795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
    Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
    Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
    Reed C; Belger M; Dell'Agnello G; Kahle-Wrobleski K; Sethuraman G; Hake A; Raskin J; Henley D
    Alzheimers Res Ther; 2018 Apr; 10(1):36. PubMed ID: 29615123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alzheimer dementia: course and burden on caregivers : Data over 18 months from German participants of the GERAS study].
    Hager K; Henneges C; Schneider E; Lieb M; Kraemer S
    Nervenarzt; 2018 Apr; 89(4):431-442. PubMed ID: 28674749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alzheimer's disease severity and its association with patient and caregiver quality of life in Japan: results of a community-based survey.
    Montgomery W; Goren A; Kahle-Wrobleski K; Nakamura T; Ueda K
    BMC Geriatr; 2018 Jun; 18(1):141. PubMed ID: 29898679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
    Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
    J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community.
    Zhu CW; Scarmeas N; Torgan R; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    J Am Geriatr Soc; 2006 Oct; 54(10):1596-602. PubMed ID: 17038080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caregivers' Sense of Coherence: Implications on Direct and Indirect Costs of Dementia Care.
    Turró-Garriga O; Viñas-Díez V; Conde-Sala JL; Calvó-Perxas L; Cullell-Juncà M; Mas-Vall-Llosera G; Flaqué M; Turon-Estrada A; Juvinyà-Canal D; Mioshi E; Garre-Olmo J
    J Alzheimers Dis; 2020; 78(1):117-126. PubMed ID: 32925037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross sectional observational study on the societal costs of Alzheimer's disease.
    Mesterton J; Wimo A; By A; Langworth S; Winblad B; Jönsson L
    Curr Alzheimer Res; 2010 Jun; 7(4):358-67. PubMed ID: 19939223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
    Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
    Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost relation between severity of Alzheimer's disease and cognitive and functional impairment].
    López-Pousa S; Garre-Olmo J; Turon-Estrada A; Hernández F; Expósito I; Lozano-Gallego M; Hernández-Ferrándiz M; Gelada-Batlle E; Pericot-Nierga I; Vilalta-Franch J
    Med Clin (Barc); 2004 May; 122(20):767-72. PubMed ID: 15207104
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.